Fulton Bank N.A. bought a new stake in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 5,384 shares of the medical research company’s stock, valued at approximately $367,000.
Other large investors have also bought and sold shares of the company. Personal CFO Solutions LLC acquired a new position in shares of Exact Sciences in the 4th quarter valued at $233,000. Regal Investment Advisors LLC boosted its position in shares of Exact Sciences by 13.6% in the 4th quarter. Regal Investment Advisors LLC now owns 8,310 shares of the medical research company’s stock valued at $615,000 after purchasing an additional 992 shares during the period. Frontier Capital Management Co. LLC boosted its position in shares of Exact Sciences by 24.1% in the 4th quarter. Frontier Capital Management Co. LLC now owns 582,221 shares of the medical research company’s stock valued at $43,073,000 after purchasing an additional 113,154 shares during the period. Altitude Crest Partners Inc. acquired a new position in shares of Exact Sciences in the 4th quarter valued at $7,334,000. Finally, Harbert Fund Advisors Inc. acquired a new position in shares of Exact Sciences in the 4th quarter valued at $507,000. Institutional investors own 88.82% of the company’s stock.
Insider Activity at Exact Sciences
In related news, EVP Brian Baranick sold 929 shares of the firm’s stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total value of $65,030.00. Following the transaction, the executive vice president now directly owns 12,758 shares of the company’s stock, valued at approximately $893,060. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 1.36% of the stock is owned by company insiders.
Analysts Set New Price Targets
View Our Latest Research Report on EXAS
Exact Sciences Stock Down 0.1 %
EXAS opened at $68.52 on Thursday. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62. The business has a 50-day moving average of $62.66 and a 200-day moving average of $56.54. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.17 and a quick ratio of 1.98. The company has a market capitalization of $12.64 billion, a PE ratio of -51.91 and a beta of 1.27.
Exact Sciences (NASDAQ:EXAS – Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.28. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The business had revenue of $699.26 million for the quarter, compared to the consensus estimate of $690.02 million. During the same period last year, the business earned ($0.45) EPS. The firm’s revenue was up 12.4% compared to the same quarter last year. Equities research analysts forecast that Exact Sciences Co. will post -0.87 EPS for the current fiscal year.
Exact Sciences Profile
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Further Reading
- Five stocks we like better than Exact Sciences
- Dividend Capture Strategy: What You Need to Know
- 3 Momentum Trades for October With Ample Upside Ahead
- Technology Stocks Explained: Here’s What to Know About Tech
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- Investing in Commodities: What Are They? How to Invest in Them
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXAS – Free Report).
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.